Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1998-04-01
2004-02-17
Martinell, James (Department: 1633)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S023100, C536S023500
Reexamination Certificate
active
06692909
ABSTRACT:
BACKGROUND OF THE INVENTION
The genomes of all organisms undergo spontaneous mutation in the course of their continuing evolution, generating variant forms of progenitor sequences (Gusella,
Ann. Rev. Biochem.
55, 831-854 (1986)). The variant form may confer an evolutionary advantage or disadvantage relative to a progenitor form or may be neutral. In some instances, a variant form confers a lethal disadvantage and is not transmitted to subsequent generations of the organism. In other instances, a variant form confers an evolutionary advantage to the species and is eventually incorporated into the DNA of many or most members of the species and effectively becomes the progenitor form. In many instances, both progenitor and variant form(s) survive and co-exist in a species population. The coexistence of multiple forms of a sequence gives rise to polymorphisms.
Several different types of polymorphism have been reported. A restriction fragment length polymorphism (RFLP) Is a variation in DNA sequence that alters the length of a restriction fragment (Botstein et al.,
Am. J. Hum. Genet.
32, 314-331 (1980)). The restriction fragment length polymorphism may create or delete a restriction site, thus changing the length of the restriction fragment. RFLPs have been widely used in human and animal genetic analyses (see WO 90/13668; W090/11369; Donis-Keller,
Cell
51, 319-337 (1987); Lander et al., Genetics 121, 85-99 (1989)). When a heritable trait can be linked to a particular RFLP, the presence of the RFLP in an individual can be used to predict the likelihood that the animal will also exhibit the trait.
Other polymorphisms take the form of short tandem repeats (STRs) that include tandem di-, tri- and tetra-nucleotide repeated motifs. These tandem repeats are also referred to as variable number tandem repeat (VNTR) polymorphisms. VNTRs have been used in identity and paternity analysis (U.S. Pat. No. 5,075,217; Armour et al.,
FEBS Lett.
307, 113-115 (1992); Horn et al., WO 91/14003; Jeffreys, EP 370,719), and in a large number of genetic mapping studies.
Other polymorphisms take the form of single nucleotide variations between individuals of the same species. Such polymorphisms are far more frequent than RFLPs, STRs and VNTRs. Some single nucleotide polymorphisms (SNP) occur in protein-coding sequences (coding sequence SNP (cSNP)), in which case, one of the polymorphic forms may give rise to the expression of a defective or otherwise variant protein and, potentially, a genetic disease. Examples of genes in which polymorphisms within coding sequences give rise to genetic disease include &bgr;-globin (sickle cell anemia), apoE4 (Alzheimer's Disease), Factor V Leiden (thrombosis), and CFTR (cystic fibrosis). cSNPs can alter the codon sequence of the gene and therefore specify an alternative amino acid. Such changes are called “missense” when another amino acid is substituted, and “nonsense” when the alternative codon specifies a stop signal in protein translation. When the cSNP does not alter the amino acid specified the cSNP is called “silent”.
Other single nucleotide polymorphisms occur in noncoding regions. Some of these polymorphisms may also result in defective protein expression (e.g., as a result of defective splicing). Other single nucleotide polymorphisms have no phenotypic effects.
Single nucleotide polymorphisms can be used in the same manner as RFLPs and VNTRs, but offer several advantages. Single nucleotide polymorphisms occur with greater frequency and are spaced more uniformly throughout the genome than other forms of polymorphism. The greater frequency and uniformity of single nucleotide polymorphisms means that there is a greater probability that such a polymorphism will be found in close proximity to a genetic locus of interest than would be the case for other polymorphisms. The different forms of characterized single nucleotide polymorphisms are often easier to distinguish than other types of polymorphism (e.g., by use of assays employing allele-specific hybridization probes or primers).
Only a small percentage of the total repository of polymorphisms in humans and other organisms has been identified. The limited number of polymorphisms identified to date is due to the large amount of work required for their detection by conventional methods. For example, a conventional approach to identifying polymorphisms might be to sequence the same stretch of DNA in a population of individuals by dideoxy sequencing. In this type of approach, the amount of work increases in proportion to both the length of sequence and the number of individuals in a population and becomes impractical for large stretches of DNA or large numbers of persons.
SUMMARY OF THE INVENTION
Work described herein pertains to the identification of polymorphisms which can predispose individuals to disease, particularly vascular pathologies, by resequencing large numbers of genes in a large number of individuals. Eighteen genes in a minimum of 30 individuals have been resequenced as described herein, and 92 SNPs have been discovered (see the Table). Forty of these SNPs are cSNPs which specify a different amino acid sequence, while 49 of the SNPs are silent cSNPs. Three of the SNPs were located in non-coding regions.
The invention relates to a gene which comprises a single nucleotide polymorphism at a specific location. In a particular embodiment the invention relates to the variant allele of a gene having a single nucleotide polymorphism, which variant allele differs from a reference allele by one nucleotide at the site(s) identified in the Table. Complements of these nucleic acid segments are also included. The segments can be DNA or RNA, and can be double- or single-stranded. Segments can be, for example, 5-10, 5-15, 10-20, 5-25, 10-30, 10-50 or 10-100 bases long.
The invention further provides allele-specific oligonucleotides that hybridize to a gene comprising a single nucleotide polymorphism or to the complement of the gene. These oligonucleotides can be probes or primers.
The invention further provides a method of analyzing a nucleic acid from an individual. The method determines which base is present at any one of the polymorphic sites shown in the Table. Optionally, a set of bases occupying a set of the polymorphic sites shown in the Table is determined. This type of analysis can be performed on a number of individuals, who are tested for the presence of a disease phenotype. The presence or absence of disease phenotype is then correlated with a base or set of bases present at the polymorphic site or sites in the individuals tested.
REFERENCES:
patent: 6451526 (2002-09-01), Song et al.
patent: 95/11995 (1995-05-01), None
patent: 95/12607 (1995-05-01), None
patent: WO-9512607 (1995-05-01), None
patent: WO-9630546 (1996-10-01), None
patent: 98/20165 (1998-05-01), None
Dürr, C., et al., “Genetic studies of antithrombin III with IEF and ASO hybridization,”Hum Genet 90:457-459 (1992).
Okajima, K., et al., “Antithrombin III Nagasaki (Ser116-Pro): A Heterozygous Variant With Defective Heparin Binding Associated With Thrombosis,”Blood 81(5):1300-1305 (1993).
Ueyama, H., et al., “Antithrombin III Kumamoto: Identification of a Point Mutation and Genotype Analysis of the Family,”Thrombosis and Haemostasis 63(2):231-234 (1990).
Zee, R.Y.L., et al., “Association and linkage analyses of restriction fragment length polymorphisms for the human renin and antithrombin III genes in essential hypertension,”Journal of Hypertension 9:825-830 (1991).
Bock, S.C., et al., “Antithrombin III Utah: Proline-407 to Leucine Mutation in a Highly Conserved Region near the Inhibitor Reactive Site,”Biochemistry 27:6171-6178 (1988).
Belgrader, P., et al., “A Multiplex PCR-Ligase Detection Reaction Assay for Human Identity Testing,”Genome Science&Technology 1(2):77-87 (1996).
Syvänen, A.-C., et al., “Identification of Individuals by Analysis of Biallelic DNA Markers, Using PCR and Solid-Phase Minisequencing,”Am. J. Hum. Genet. 52:46-59 (1993).
Wang, D., et al., “Toward a third generation genetic map of the human genome based on bi-a
Cargill Michele
Daley George Q.
Ireland James S.
Lander Eric S.
Rozen Steven G.
Hamilton, Brook, Smith & Reynolds, P.C
Martinell James
Whitehead Institute for Biomedical Research
LandOfFree
Coding sequence polymorphisms in vascular pathology genes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Coding sequence polymorphisms in vascular pathology genes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Coding sequence polymorphisms in vascular pathology genes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3306382